SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
Daniele Focosi, Marco Tuccori, Andreina Baj, Fabrizio Maggi
Abstract
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
Topics & Concepts
Convalescent plasmaMonoclonal antibodyVirologyAntibodyIn vitroSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)ImmunologyBiologyInternal medicineGeneticsInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies